β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer

被引：86

作者：

Blandin, Anne-Florence ^{[1
]}

Renner, Guillaume ^{[1
]}

Lehmann, Maxime ^{[1
]}

Lelong-Rebel, Isabelle ^{[1
]}

Martin, Sophie ^{[1
]}

Dontenwill, Monique ^{[1
]}

机构：

[1] Univ Strasbourg, Dept Tumoral Signaling & Therapeut Targets, CNRS, Fac Pharm,UMR7213, Illkirch Graffenstaden, France

来源：

FRONTIERS IN PHARMACOLOGY | 2015年 / 6卷

关键词：

integrins; hallmarks of cancer; proliferation; migrationinvasion; resistance to cell death; angiogenesis; therapeutic target; SQUAMOUS-CELL CARCINOMA; INTEGRIN-LINKED KINASE; ALPHA-5-BETA-1; INTEGRIN; ALPHA-2-BETA-1; ANTIANGIOGENIC THERAPY; ANOIKIS RESISTANCE; SIGNALING PATHWAY; ADHESION KINASE; GROWTH-FACTORS; TUMOR-GROWTH;

D O I：

10.3389/fphar.2015.00279

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Integrins belong to a large family of alpha beta heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pathways in response to structural variations of the extracellular matrix. Biochemical and biomechanical cues provided by this matrix and transmitted to cells via integrins are critically modified in tumoral settings. lntegrins repertoire are subjected to expression level modifications, in tumor cells, and in surrounding cancer-associated cells, implicated in tumor initiation and progression as well. As critical players in numerous cancer hallmarks, defined by Hanahan and Weinberg (2011), integrins represent pertinent therapeutic targets. We will briefly summarize here our current knowledge about integrin implications in those different hallmarks focusing primarily on beta 1 integrins.

引用

页数：10

共 144 条

[1] Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J].